scholarly journals Bariatric surgery reverses metabolic risk in patients treated in outpatient level

2014 ◽  
Vol 27 (1) ◽  
pp. 38-42 ◽  
Author(s):  
Epifânio Feitosa da SILVA-NETO ◽  
Cecília Mª Passos VÁZQUEZ ◽  
Fabiana Melo SOARES ◽  
Danielle Góes da SILVA ◽  
Márcia Ferreira Cândido de SOUZA ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Life Expectancy ◽  
Conventional Treatment ◽  
Cardiometabolic Risk ◽  
Metabolic Risk ◽  
Outpatient Basis ◽  
Treatment Of Obesity

Background : The conventional treatment of obesity presents unsatisfactory results on weight loss and its long-term sustainability, therefore bariatric surgery has been suggested as an effective therapy, determining sustainable long-term weight loss, reversal of components of cardiometabolic risk and improved quality and life expectancy. Aim : To investigate the clinical component of the cardiometabolic risk in patients undergoing bariatric surgery assisted on outpatient basis. Methods : The sample consisted of 47 patients with ages between 18 and 60 years, 72% females. Diabetes mellitus, hypertension, and dyslipidemia were prospectively evaluated by using the Assessment of Obesity-Related Co-morbidities scale. Results : Occurred improvement in these co-morbidities within 12 months after surgery. Co-morbidities resolved were greater than those improved. Conclusion : The study revealed that the Assessment of Obesity-Related Co-morbidities is a system that can be effectively used to quantify the degree of reduction of the severity of the cardiometabolic risk in response to bariatric surgery.

scholarly journals Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant

2007 ◽  
Vol 10 (10A) ◽  
pp. 1200-1205 ◽  
Author(s):  
Miguel A Rubio ◽  
Manuel Gargallo ◽  
Ana Isabel Millán ◽  
Basilio Moreno
Keyword(s):  
Risk Factors ◽  
Weight Loss ◽  
Cardiometabolic Risk ◽  
The Body ◽  
Cardiometabolic Risk Factors ◽  
Phase Iii ◽  
Diabetic Patients ◽  
Long Term Treatment ◽  
Treatment Of Obesity

AbstractBackgroundModification of lifestyle is the main therapeutical approach in the treatment of obesity, but use to fail on long terms of time. Addition of anti-obesity drugs allows keeping the weight loss during years and improving obesity-related comorbidities.MethodsThis review is an actualisation on efficacy, safety and tolerability of the approved drugs on the long-term treatment of obesity (orlistat and sibutramine). New indications and effects of their use far beyond the weight loss are as well commented. Finally, potential benefits of the administration of CB1 antagonist rimonabant on the weight loss and cardiometabolic risk factors are analysed in detail.DiscussionA decade of experience on the use of orlistat and sibutramine has demonstrated their higher efficacy on the weight loss when compared to placebo either on adult or teenage population as well as safety and tolerability on long-term administration. Beneficial effects on the lipid profile, glycosilated haemoglobin on diabetic patients, blood pressure and levels of inflammatory cytokines, contribute to decrease the cardiovascular risk on obese patients. Phase III clinical trials using rimonabant show additional benefits to the expected weight loss, mainly reducing visceral fat and cardiometabolic risk factors.ConclusionPharmacological treatment of obesity must be considered as a therapeutical tool that has to be used together with long-term lifestyle changes, contributing to the body weight reduction as well as to the improvement of the cardiometabolic risk related to obesity.

scholarly journals The adolescent with obesity: what perspectives for treatment?

2022 ◽  
Vol 48 (1) ◽  
Author(s):  
Antonio Nicolucci ◽  
Claudio Maffeis
Keyword(s):  
Risk Factors ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Cardiometabolic Risk ◽  
Public Health Problem ◽  
Overweight And Obesity ◽  
Cardiometabolic Risk Factors ◽  
Major Public Health Problem ◽  
Lifestyle Interventions

AbstractThe dramatic increase in overweight and obesity among children and adolescents has become a major public health problem. Obesity in children and young adults is associated with an increased prevalence of cardiometabolic risk factors. Obesity during adolescence represents a strong predictor of obesity and higher mortality in adulthood. Due to the serious implications of obesity in adolescents, effective treatments are urgently needed. Lifestyle interventions represent the recommended therapy. Nevertheless, real world data show that the majority of adolescents do not achieve weight loss in the long term, and are reluctant to participate in lifestyle interventions. Pharmacological treatment is recommended if a formal lifestyle modification program fails to limit weight gain or to improve comorbidities. However, until 2020 the European Medicines Agency (EMA) had not approved any pharmacotherapeutic agents for obesity in pediatric patients. On April 2021, EMA has authorized the use of Liraglutide, a glucagon-like peptide (GLP)-1 analog, for the treatment of obesity in adolescents (12–17 years). The efficacy and safety of Liraglutide were demonstrated in a randomized, double-blind trial, enrolling 251 adolescents. After 56 weeks, a reduction in BMI of at least 5% was observed in 43.3% of participants in the liraglutide group vs. 18.7% in the placebo group, and a reduction in BMI of at least 10% was observed in 26.1 and 8.1%, respectively. Gastrointestinal events were the events most frequently reported with liraglutide. Bariatric surgery represents another effective treatment for adolescents with severe obesity, with sustained benefits on weight loss and cardiometabolic risk factors. However, long-term safety and effectiveness data in adolescents are still scarce. Risks of bariatric surgery include the need for additional abdominal surgical procedures and specific micronutrient deficiencies. Hopefully, new pharmacological treatments in addition to lifestyle interventions will offer more chances of success.

scholarly journals Surgical treatment of obesity

2008 ◽  
Vol 158 (2) ◽  
pp. 135-145 ◽  
Author(s):  
Mariëlle J F Bult ◽  
Thijs van Dalen ◽  
Alex F Muller
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Conventional Treatment ◽  
Polycystic Ovary ◽  
Overweight And Obesity ◽  
Joint Disease ◽  
Long Term Effects ◽  
Obstructive Sleep ◽  
Long Term Treatment

More than half of the European population are overweight (body mass index (BMI) >25 and <30 kg/m2) and up to 30% are obese (BMI≥30 kg/m2). Being overweight and obesity are becoming endemic, particularly because of increasing nourishment and a decrease in physical exercise. Insulin resistance, type 2 diabetes, dyslipidemia, hypertension, cholelithiasis, certain forms of cancer, steatosis hepatis, gastroesophageal reflux, obstructive sleep apnea, degenerative joint disease, gout, lower back pain, and polycystic ovary syndrome are all associated with overweight and obesity. The endemic extent of overweight and obesity with its associated comorbidities has led to the development of therapies aimed at weight loss. The long-term effects of diet, exercise, and medical therapy on weight are relatively poor. With respect to durable weight reduction, bariatric surgery is the most effective long-term treatment for obesity with the greatest chances for amelioration and even resolution of obesity-associated complications. Recent evidence shows that bariatric surgery for severe obesity is associated with decreased overall mortality. However, serious complications can occur and therefore a careful selection of patients is of utmost importance. Bariatric surgery should at least be considered for all patients with a BMI of more than 40 kg/m2 and for those with a BMI of more than 35 kg/m2 with concomitant obesity-related conditions after failure of conventional treatment. The importance of weight loss and results of conventional treatment will be discussed first. Currently used operative treatments for obesity and their effectiveness and complications are described. Proposed criteria for bariatric surgery are given. Also, some attention is devoted to more basic insights that bariatric surgery has provided. Finally we deal with unsolved questions and future directions for research.

scholarly journals Through Thick and Thin: Identifying Barriers to Bariatric Surgery, Weight Loss Maintenance, and Tailoring Obesity Treatment for the Future

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Donevan Westerveld ◽  
Dennis Yang
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Weight Control ◽  
Weight Loss Maintenance ◽  
The United States ◽  
Physician Perceptions ◽  
Perceptions And Attitudes ◽  
Treatment Of Obesity ◽  
Weight Loss Interventions

More than one-third of the adults in the United States are obese. This complex metabolic disorder is associated with multiple comorbidities and increased all-cause mortality. Bariatric surgery has been shown to be more effective than medical therapy and has been associated with weight loss maintenance and decreased mortality. In spite of these well-established benefits, less than 1% of candidates undergo surgery due to multiple factors, such as patient and physician perceptions and attitudes, patient-physician interaction, lack of resources, and cost burden. Furthermore, even in patients who do undergo bariatric surgery and/or alternate weight loss interventions, long-term weight control is associated with high-risk failure and weight regain. In this review, we highlight some of the current barriers to bariatric surgery and long-term weight loss maintenance and underscore the importance of an individualized multidisciplinary longitudinal strategy for the treatment of obesity.

Abstract #240 Weight Loss Trajectory Following Randomization to Bariatric Surgery on Long-Term Diabetes Outcomes

2018 ◽  
Vol 24 ◽  
pp. 49
Author(s):  
Keren Zhou ◽  
Kathy Wolski ◽  
Ali Aminian ◽  
Steven Malin ◽  
Philip Schauer ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Diabetes Outcomes ◽  
Trajectory Following

Long-Term Weight Loss and Psychological Functioning in Bariatric Surgery Patients

2012 ◽  
Author(s):  
Leslie M. Schuh ◽  
David B. Creel ◽  
Joseph Stote ◽  
Katharine Hudson ◽  
Karen K. Saules ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Psychological Functioning

scholarly journals Long-Term Iron and Vitamin B12 Deficiency Are Present after Bariatric Surgery, Despite the Widespread Use of Supplements

2021 ◽  
Vol 18 (9) ◽  
pp. 4541
Author(s):  
Mauro Lombardo ◽  
Arianna Franchi ◽  
Roberto Biolcati Rinaldi ◽  
Gianluca Rizzo ◽  
Monica D’Adamo ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
Ideal Body Weight ◽  
Excess Weight ◽  
Nutritional Deficiencies ◽  
Average Percentage ◽  
Nutritional Studies

There are few long-term nutritional studies in subjects undergoing bariatric surgery that have assessed weight regain and nutritional deficiencies. In this study, we report data 8 years after surgery on weight loss, use of dietary supplements and deficit of micronutrients in a cohort of patients from five centres in central and northern Italy. The study group consisted of 52 subjects (age: 38.1 ± 10.6 y, 42 females): 16 patients had Roux-en-Y gastric bypass (RYGB), 25 patients had sleeve gastrectomy (SG) and 11 subjects had adjustable gastric banding (AGB). All three bariatric procedures led to sustained weight loss: the average percentage excess weight loss, defined as weight loss divided by excess weight based on ideal body weight, was 60.6% ± 32.3. Despite good adherence to prescribed supplements, 80.7% of subjects (72.7%, AGB; 76.7%, SG; 93.8 %, RYGB) reported at least one nutritional deficiency: iron (F 64.3% vs. M 30%), vitamin B12 (F 16.6% vs. M 10%), calcium (F 33.3% vs. M 0%) and vitamin D (F 38.1% vs. M 60%). Long-term nutritional deficiencies were greater than the general population among men for iron and among women for vitamin B12.

Grazing Behavior Hinders Weight Loss in Long-Term Post Bariatric Surgery: a Cross-Sectional Study

2021 ◽  
Author(s):  
Larissa Cristina Lins Berber ◽  
Mariana Silva Melendez-Araújo ◽  
Eduardo Yoshio Nakano ◽  
Kênia Mara Baiocchi de Carvalho ◽  
Eliane Said Dutra
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Grazing Behavior ◽  
Post Bariatric Surgery

scholarly journals Recent Advances in Gestational Diabetes Mellitus

2021 ◽  
Vol 10 (10) ◽  
pp. 2202
Author(s):  
Katrien Benhalima
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Clinical Medicine ◽  
Metabolic Risk ◽  
Special Issue ◽  
Recent Advances ◽  
Adverse Pregnancy ◽  
New Biomarkers

The incidence of gestational diabetes mellitus (GDM) and overt diabetes in pregnancy is rising globally. GDM leads to increased risks for maternal and neonatal adverse pregnancy outcomes. In addition, GDM is also associated with an increased long-term metabolic risk in mothers and offspring [1]. Although much is known about GDM, evidence gaps persist. For instance, more research is needed on how to prevent GDM, on whether screening and treatment of GDM in early pregnancy are beneficial, on non-fasting biomarkers to screen for GDM, on new biomarkers to predict pregnancy complications, and on how to reduce the long-term metabolic risk in mothers and infants after delivery. To address this important health issue, the present Special Issue in the Journal of Clinical Medicine was dedicated to recent advances in the field of GDM. This Special Issue published 16 articles on this topic. [...]

Sign in / Sign up

Export Citation Format

Share Document